drugset / Trial / NCT07013279
Evaluate the Efficacy and Safety of DWP712 With Moderate to Severe Glabellar Lines
RandomizedParallel-groupDouble-blindTreatment
Summary
To evaluate the efficacy and safety of DWP712 Inj. in Subjects with Moderate to Severe Glabellar Lines
Timeline
- Start
- 2025-07-15
- Primary completion
- 2025-12-31
- Completion
- 2026-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Botulinum toxin type A | Protein / enzyme biologic | 20 iu | Intramuscular |
| Subject | DWP712 | Unknown | 20 iu | Intramuscular |
Indications
No indication recorded.